What's the best way for pharmaceutical companies to get medical insurance? Not always!

[industry trends of pharmaceutical network] recently, the results of a new round of national health insurance negotiation have been announced This negotiation is not only concerned by practitioners, investors, clinicians and patients in the pharmaceutical industry, but also reported by some financial and pharmaceutical media for several consecutive days, making it a hot topic of common concern in the entire pharmaceutical industry Although the negotiation results make several enterprises happy and worried, when reviewing the negotiation process, it can be found that most pharmaceutical companies have made great efforts to enter the medical insurance catalog, and even spared no effort to fight the price war So why do pharmaceutical companies want to enter the medical insurance catalog so actively? After all, there are still many people in the industry who think that new drugs are not necessary to enter the medical insurance, and attractive products have unblocked out of hospital channels and considerable sales volume In my opinion, this may be because the first advanced medical insurance is almost the prerequisite for entering the hospital at present The compliance of patients to take medicine in the hospital is n times higher than that to go out of the hospital Moreover, some hospital nurses are not willing to inject patients to buy medicine outside the hospital Secondly, after entering the medical insurance, the hospital can also occupy a more favorable position in the "stop and limit control" of drugs, without too much market risk Because of the above reasons, most of the representatives of pharmaceutical companies in the industry are keen to enter the medical insurance catalog In fact, the negotiation of medical insurance is only a common means of drug negotiation in the world Although there is no doubt about its effectiveness, the previous domestic drug purchase market is still in the initial stage There are both national and local negotiations in the negotiation of medical insurance, and the rules are relatively chaotic, which leads to a certain impact on the enthusiasm and effectiveness of the domestic negotiation of medical insurance, which needs to be improved At present, on the whole, the price for quantity method used by pharmaceutical companies to enter the national health insurance does not necessarily mean that everything is going well From the actual sales of more than 20 drugs in the medical insurance negotiation in 2017 and cancer drug negotiation in 2018, we can see that, including the famous good drugs such as lilalutide, tegrilol, trastuzumab, etc., have all entered the national medical insurance through the method of price for quantity Although there are many successful varieties, the price has decreased and the sales volume is not high, and the limited profit is not high Yes Industry insiders said that this may be because some enterprises did not keep up with the volume after price reduction Therefore, it is very important to negotiate whether the products can be released, especially whether they can be continuously released However, according to the implementation progress and overall speed of medical insurance in different places, the welfare of medical insurance for pharmaceutical enterprises is also different Generally speaking, the more sound the health insurance system, the better the drug sales In addition, the current national medical reform and medical insurance policy in the retail terminal implementation is not ideal, many local retail terminals still can not use the medical insurance card, and the different medical insurance policies will also lead to the medical insurance role can not be fully played As a result of all of the above, it will have a certain impact on the volume of pharmaceutical enterprises This year, a person in charge of a pharmaceutical enterprise selected into this year's medical insurance catalog told reporters that he hoped that relevant departments would introduce supporting measures as soon as possible in terms of the promotion of hospital drug delivery, the establishment of designated medical insurance pharmacies and the general control policy of medical insurance In addition, the promotion work after entering the medical insurance is also very important for pharmaceutical enterprises Many pharmaceutical enterprises should actively change their own marketing mode, instead of selling according to the traditional routine and rhythm of a few years ago We should know that the national health insurance talks not only changed the rules of the game of drug access, but also changed the rules of marketing and promotion Pharmaceutical companies that do not follow the new rules will find that the medical insurance tickets they spend a lot of money on may not get back the expected return.